Stocktoria
Vicapsys Life Sciences, Inc. VICP
OTC · stock · Pharmaceutical Preparations · website · IPO 2001-07-11
Vicapsys Life Sciences, Inc. financials (annual, from 10-K)
Bars are annual figures from 2019 to 2023; red bars are negative (a loss or cash outflow).
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| R&D expense | $15,267 | $13,097 | $17,698 | $102,180 | $98,983 |
| Operating income | -$1.0M | -$984,790 | -$336,871 | -$765,844 | — |
| Net income | -$1.2M | -$984,790 | -$236,871 | -$765,844 | -$1.4M |
| EPS (diluted) | $-0.03 | $-0.03 | — | — | — |
| Operating cash flow | -$417,524 | -$238,197 | -$443,974 | -$262,897 | -$970,264 |
| Cash & equivalents | $9,422 | $14,097 | $217,295 | $1,269 | $264,166 |
| Total assets | $39,656 | $72,021 | $594,313 | $404,118 | $698,439 |
| Shareholders' equity | -$1.9M | -$950,791 | -$121,651 | -$449,106 | $301,957 |
Source: SEC EDGAR filings · CIK 0001468639 · US · as of 2023-12-31. facts plus Stocktoria's own computed scores — not investment advice.